Decan,Re: "Assuming that GBI’s pending pivotal data is...

Decan,

Re: "Assuming that GBI’s pending pivotal data is equivalent to the Oct 2008 data PapType is in a very strong position to capture a significant % of these markets in the ASCUS/Triage indication…say 30-35%...Sonic Healthcare are also the largest independent pathology provider in Europe"

30-35% seems like a very high assumption. What do you base the percentages on?

Also, what is the likely effect of competition on these percentages, for new tests such as the ones that are being sponsored in relation to the Bill & Melinda Gates foundation program etc. (I can't remember the details, it's late!) and possibly other variants of existing players and new entrants?

Cheers.